DI DAWSONJAMES

INSTITUTIONAL RESEARCH *Diagnostics-Therapeutics* UPDATE REPORT

Member FINRA/SIPC

Toll-Free: 866-928-0928 • www.DawsonJames.com • 101 North Federal Highway - Suite 600 • Boca Raton, FL 33432

Aditxt Therapeutics (NASDAQ: ADTX)

Aditxt (ADTX)-Neutral Rated: Acquires MDNA

Aditxt is acquiring MDNA Life Sciences for 50k shares of Aditxt stock & an equal number of warrants plus 5k shares of subsidiary Pearsanta's preferred stock with a value of \$25M, and payments of up to \$3.2M to be made to MDNA. Is it a good deal? Our gut reaction is the price seems rich and the pipeline (mitochondrial DNA diagnostics) seems early but mitochondrial DNA does represent promise.

Investment Highlights

What is it, and what does Aditxt get? We have not yet spoken with management and as such not yet made any changes to our model, which admittedly is out of date.

MDNA's Mitomic technology provides a tool for identifying biomarkers associated with various diseases that lead to mtDNA mutations. The platform includes a biomarker portfolio addressing a range of health concerns beyond oncology, extending into areas of medical need. The technology has uncovered biomarkers and generated an in-silico database through computer simulations. Highlights from the asset portfolio include:

- The Mitomic Endometriosis Test is in development as a blood-based assay for diagnosis of endometriosis. This test aims to provide early diagnostic insights, potentially reducing delays in diagnosing endometriosis.
- The Mitomic Prostate Test is currently under development as a blood-based assay for diagnosis of prostate cancer. We believe that this test holds the potential to provide more specific and clinically informative data, especially in the prostatespecific antigen (PSA) grey zone. It aims to address the challenges of over-diagnosis and mitigate risks associated with low-grade cancers.
- The development pipeline includes tests for various cancers such as ovarian, lung, pancreatic, liver, breast, stomach, esophageal, and colorectal cancer. The goal is to enhance clinical outcomes by offering non-invasive/minimally invasive testing at the early stages of disease progression.

Valuation: Our valuation for Aditxt was originally driven by diagnostic testing and the expansion of that testing into the type 1 diabetes at-risk testing market as well as some Covid testing. That model is now in question as diagnostics revenue has yet to gain any meaningful traction. A 1:40 reverse split (July 23) and several dilutive raises is now followed by a significant acquisition involving stock (50k stock & warrants). The Evofem acquisition (closes 1H24) and MDNA now too, may represent some "hope" to the Aditxt story. We remain on the sidelines with a neutral rating.

Risks to our thesis include: (1) commercial; (2) financial; (3) intellectual property; (4) regulatory and (5) OEM and/or manufacturing (6) Acquisition and Integration. We review these risks in the Risks Analysis section of this report.

January 9, 2024

Jason H. Kolbert

Managing Director and Senior Analyst jkolbert@dawsonjames.com





Risk Analysis

Regulatory Risk. There can be no assurances that the company will be able to secure the required regulatory approvals to support its business.

Commercial risk. The focus of the company is on successfully developing its products and bringing them to the market. Competition may be intense from external players as well as customers who choose to "build it themselves."

Financial risk. The company may need to raise capital in the marketplace relatively soon. There can be no assurance that the company will be able to raise capital and do so on favorable terms successfully.

Intellectual property risk. The company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and the company may infringe on third parties' patents.

OEM and/or manufacturing risk. Original Equipment Manufacturers (OEMs) may decide to make products themselves, and, as such, terminate production contracts before completion, creating revenue shortfalls. Manufacturing risks include the ability to produce and do so in a competitive, timely, and efficient way.


Acquisition and Integration: Aditxt hopes to acquire and integrate new companies and or pipeline products into the company. There can be no assurance that this strategy will be successful and that the currently proposed acquisitions will come to fruition.

Exhibit 1. Income Statement

ADTX., Inc. Income Statement (\$000)															
YE Dec. 31	2020A	2021A	2022A	1Q23A	2Q23A	3Q23A	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Revenue (\$000)															
COVID-MaB Testing		-	934	218	221	124	136	700	1,000	1,200	1,260	1,323	1,389	1,459	1,532
Total Revenues	-	105	934	218	221	124	136	700	1,000	1,200	1,260	1,323	1,389	1,459	1,532
Expenses															
COGS	-	78	767	178	186	107	112	583	600	600	630	662	695	729	766
% COGS			82%	82%	82%	82%	82%	83%	60%	50%	50%	50%	50%	50%	50%
Gross Profit	-	27	167	40	35	18	24	117	400	600	630	662	695	729	766
Sales (Advertising & Marketing) expense	12	335	1,849	66	114	44	76	300	6,000	6,120	6,242	6,367	6,495	6,624	6,757
General and administrative	7,852	22,084	15,986	4,369	3,671	7,170	4,790	20,000	9,000	9,180	9,364	9,551	9,742	9,937	10,135
Research & Development	82	5,043	7,268	1,388	485	899	1,229	4,000	4,080	4,162	4,245	4,330	4,416	4,505	4,595
Impairment on Notes receivable		14,500	544												
Total expenses	8,872	41,962	25,647	5,822	4,270	8,113	6,096	24,300	19,080	19,462	19,851	20,248	20,653	21,066	21,487
Operating Profit	(8,872)	(41,935)	(25,480)	(5,782)	(4,234)	(8,095)	(6,071)	(24,183)	(18,680)	(18,862)	(19,221)	(19,586)	(19,958)	(20,337)	(20,721)
Oper Margin															
Interest expense	(10)	(93)	(753)	(198)	(1,285)	(906)		(2,390)	-	-	-	-	-	-	-
Amortization of Debt Discount	1	3	(1,476)	(4)	180	(378)		(202)	-	-	-	-	-	-	-
Other (loss)	(268)	(4,346)	59					-	-	-	-	-	-	-	-
Pre-tax income	(9,149)	(46,371)	(27,650)	(5,985)	(5,682)	(9,745)	(6,071)	(27,483)	(18,680)	(18,862)	(19,221)	(19,586)	(19,958)	(20,337)	(20,721)
Pretax Margin			_					_	_						
Income Tax (Benefit)			-	-	-	-		-	-	-					
Tax Rate			0%	0%	0%	0%	0%	0%	0%	0%					
GAAP Net Income	(9,149)	(46,371)	(27,612)	(5,985)	(5,682)	(9,913)	(6,071)	(27,651)	(18,680)	(18,862)	(19,221)	(19,586)	(19,958)	(20,337)	(20,721)
GAAP-EPS	(1.33)	(2.43)	(14.89)	(1.31)	(0.92)	(48.77)	(29.81)	(80.82)	(91.26)	(91.97)	(93.53)	(95.12)	(96.73)	(98.37)	(100.03)
Non GAAP EPS (dil)	(1.33)	(1.56)	(14.89)	(1.31)	(0.92)	(48.77)	(29.81)	(80.82)	(91.26)	(91.97)	(93.53)	(95.12)	(96.73)	(98.37)	(100.03)
Wgtd Avg Shrs (Bas) - '000s	6,903	19,091	1,855	4,563	6,177	203	204	2,787	205	206	208	210	211	213	215
Wgtd Avg Shrs (Dil) - '000s	6,903	32,123	1,855	4,563	6,177	203	204	2,787	205	205	205	206	206	207	207

Source: Dawson James estimates, company reports

Important Disclosures:



Price target and ratings changes over the past three years: Initiated – Buy – February 4, 2021 – Price Target \$14.00 Update - Buy - March 25, 2021 - Price Target \$14.00 Update - Buy - April 8, 2021 - Price Target \$14.00 Update - Buy - June 1, 2021 - Price Target \$14.00 Update - Buy - July 12, 2021 - Price Target \$14.00 Price Target Change - Buy - August 16, 2021 - Price Target Lowered to \$8.00 from \$14.00 Price Target Change – Buy – November 18, 2021 – Price Target Lowered to \$4.00 from \$8.00 Price Target Change - Buy - December 23, 2021 - Price Target Raised from \$4.00 to \$6.00 Update - Buy - April 5, 2022 - Price Target \$6.00 Price Target Change - Buy - August 16, 2022 - Price Target \$1.00 Price Target Lowered \$6.00 to \$1.00 Rating Change - Lowering from Buy to Neutral - September 16, 2022 Price Target - NA Update - Neutral - October 24, 2022 - Price Target - NA Update - Neutral - January 31, 2023 - Price Target - NA Update - Neutral - April 18, 2023 - Price Target - NA Update - Neutral - January 4, 2024 - Price Target - NA

Update - Neutral - January 9, 2024 - Price Target - NA

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of December 14, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

DAWSONJAMES

- 1) **Buy**: The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months.
- 2) **Neutral**: The analyst believes the price of the stock is fairly valued for the next 12-18 months.
- 3) **Sell**: The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as or	14 DCC 25			
	Company		Investment	
	Coverage		Banking	
				% of
Ratings Distribution	# of Companies	% of Total	# of Companies	Totals
Market Outperform (Buy)	21	61.76%	4	11.80%
Market Perform (Neutral)	13	38.24%	2	5.90%
Market Underperform (Sell)	0	0%	0	0%
Total	34	100%	6	17.70%

Current as of 14-Dec-23

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.